ProShare Advisors LLC raised its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 59.8% during the second quarter, HoldingsChannel reports. The firm owned 22,152 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,293 shares during the quarter. ProShare Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $593,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at $33,000. EntryPoint Capital LLC acquired a new position in shares of Supernus Pharmaceuticals in the first quarter valued at about $43,000. Meeder Asset Management Inc. purchased a new position in shares of Supernus Pharmaceuticals in the second quarter worth about $47,000. Innealta Capital LLC purchased a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Finally, nVerses Capital LLC acquired a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $72,000.
Supernus Pharmaceuticals Price Performance
Shares of NASDAQ:SUPN opened at $30.75 on Monday. Supernus Pharmaceuticals, Inc. has a 1 year low of $21.99 and a 1 year high of $35.44. The firm has a market capitalization of $1.69 billion, a PE ratio of -106.03 and a beta of 0.88. The business’s 50 day moving average price is $32.27 and its 200-day moving average price is $30.39.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on SUPN shares. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Piper Sandler downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $41.00 to $36.00 in a report on Wednesday, September 11th.
Read Our Latest Stock Report on SUPN
Supernus Pharmaceuticals Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
See Also
- Five stocks we like better than Supernus Pharmaceuticals
- Using the MarketBeat Dividend Tax Calculator
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Consumer Discretionary Stocks Explained
- CarMax’s Impressive Rally: What Investors Should Watch Next
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 9/23 – 9/27
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.